Regarding studies with human biopsies, the evidence around CNT2 is controversial: while one study indicates that high expression of this protein correlates with a poor response to neoadjuvant concurrent chemoradiotherapy and worse patient outcomes for survival in rectal cancer [56], another study indicates that CNT2 expression is significantly repressed in colorectal cancer [57]. The gene discussed is SLC28A2; the disease is rectal cancer.